Highlights• A new analysis indicates that radiocontrast, which is commonly used during imaging tests, may be less hazardous to the kidneys than previously thought.• Among nearly 6 million hospitalized patients, those who received radiocontrast did not develop acute kidney injury at a clinically significant higher rate than other patients.
Newswise — Washington, DC (September 29, 2016) — A new analysis indicates that radiocontrast, which is commonly used during selected imaging tests may be less hazardous than previously thought. The findings, which appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN), suggest that imaging studies that might help save or improve lives are being unnecessarily withheld from patients owing to exaggerated fears.
While radiocontrast—sometimes referred to simply as “contrast” or “dye”—is frequently used to enhance imaging with computed tomography scans or angiography, it can contribute to acute kidney injury (AKI). There is little agreement in the medical literature regarding the incidence of contrast-induced AKI, with published rates ranging from <1% to >30% of exposed patients.
To provide a more accurate estimate of the burden of AKI among patients receiving radiocontrast, Emilee Wilhelm-Leen, MD, Maria Montez-Rath, PhD, and Glenn Chertow, MD, MPH (Stanford University School of Medicine) analyzed 2009 information from the Nationwide Inpatient Sample, the largest publically available all-payer inpatient care database in the United States. After restricting the sample to hospitalizations for patients older than 18 years with lengths of stay ≤10 days, the investigators were left with 5,931,523 hospitalizations for analysis.
The researchers stratified patients according to the presence or absence of 12 relatively common diagnoses associated with AKI and evaluated rates of AKI between strata. They also created a model that controlled for patients’ health and comorbidities to estimate the risk of AKI associated with radiocontrast administration within each strata.
The team found that, in general, patients who received contrast did not develop AKI at a clinically significant higher rate than other patients. Patients who received radiocontrast developed AKI at a rate of 5.5%, compared with 5.6% of patients who did not receive radiocontrast. After controlling for patients’ health and comorbidities, radiocontrast administration was actually linked to a 7% lower likelihood of developing AKI.
“We show data suggesting that the risk of acute kidney injury related to radiocontrast administration has been overestimated, and we would like for physicians, including cardiologists, radiologists, and surgeons who frequently are faced with decisions regarding the use or non-use of radiocontrast-enhanced imagining studies, to take this information into account in their clinical decision-making,” said Dr. Chertow.
Disclosures: The authors reported no financial disclosures.
The article, entitled “Estimating the Risk of Radiocontrast-Induced (Associated) Nephropathy,” will appear online at http://jasn.asnjournals.org/ on September 29, 2016, doi: 10.1681/ASN.2016010021.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has nearly 16,000 members representing 112 countries. For more information, please visit www.asn-online.org or contact us at 202-640-4660.# # #
RSS